Brought to you by 
BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics; option exercised
02 Aug 2022
Executive Summary
Boehringer Ingelheim Pharmaceuticals Inc. entered into a collaboration with ViraTherapeutics GMBH to develop a next generation oncolytic virus platform based on ViraTherapeutics' lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) currently in preclinical development for solid cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes M&A Option
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics; option exercised
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice